[BMJ]
OP0129 A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF RUZINURAD (SHR4640) IN COMBINATION WITH FEBUXOSTAT FOR PRIMARY GOUT AND HYPERURICEMIA WITH AN INADEQUATE RESPONSE TO FEBUXOSTAT ALONE
文献作者：C. Bao; H. Ding; Q. Dai; J. Hu; L. Yang; Z. Jiang; X. Xu; C. Lin; H. Wei; Q. Xie; Y. Zhuang; X. Shi; J. Wen; L. Tang; G. Shi; X. He; L. Qian; W. Hu; Y. Ma; G. Dong
30